Wei Liu

Prof. Wei Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2024 in Nitric Oxide
Verified
Journal Article
Closed access
XFXiaoming Fu
Xiaoming Fu
HLHaowei Lu
Haowei Lu
MGMeng Gao
Meng Gao
PLPinghe Li
Pinghe Li
YHYan He
Yan He
WLWei Liu
Wei Liu

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
HLHailey R. Lee
Hailey R. Lee
EAEvan R. Abt
Evan R. Abt
KRKhalid Rashid
Khalid Rashid
ACAmanda L. Creech
Amanda L. Creech
KLKeke Liang
Keke Liang
TLThuc M. Le
Thuc M. Le
Stimulator of interferon genes (STING) coordinates innate and adaptive immune responses by mediating type I interferon and NF-κB signaling and is therefore a promising cancer immunotherapy target. While first generation STING agonists have advanced to multiple clinical trials, their application is restricted to intratumoral administration and these agents have shown limited therapeutic efficacy. In contrast, recently developed second generation STING agonists allow for systemic administration and have been shown to exert highly potent anti-tumor effects in animal models of cancer. However, STING is expressed in a wide array of cell types and tissues, and the effects of systemic activation of this pattern recognition receptor are poorly understood. This highlights the need for the development of pharmacodynamic companion biomarkers that can be used to guide the clinical development of newly developed systemic STING agonists. Here, we show that systemic administration of the STING agonist diABZI triggers alterations in glucose metabolism in immune cells which can be detected non-invasively using [18F]Fluorodeoxyglucose (FDG) and positron emission tomography (PET). Accordingly, systemic STING activation significantly upregulated [18F]FDG uptake in secondary lymphoid organs, such as the spleen and lymph nodes, as indicated by PET imaging in vivo and confirmed by gamma counter measurements of isolated splenocytes ex vivo. Importantly, STING agonist-induced changes in [18F]FDG uptake in the spleen and lymph nodes were highly predictive of therapeutic responses to STING agonist mono- and combination therapies in animal models of pancreatic cancer. Using single-cell RNA sequencing we found that systemic STING activation triggers profound transcriptional alterations in T and B lymphocytes indicative of a metabolic shift towards enhanced glycolysis. We then explored whether metabolic alterations indicated by increased [18F]FDG uptake are associated with changes in the functional phenotypes of T and B cells. We found that systemic STING activation induced the upregulation of the early activation marker CD69 and immune checkpoint ligand PD-L1. Furthermore, CD69 and PD-L1 upregulation occurred in a STING agonist dose-dependent manner that correlated with [18F]FDG uptake as measured non-invasively by PET. In interferon receptor knockout mice, CD69 and PD-L1 expression was partially attenuated; however, [18F]FDG uptake was still induced following STING activation, suggesting that an interferon-independent mechanism mediates the observed glycolytic switch in lymphocytes. In summary, [18F]FDG-PET provides a novel non-invasive and widely applicable pharmacodynamic biomarker which has potential to guide and accelerate the clinical development of systemic STING agonist-based immunotherapies in immunologically cold malignancies. Citation Format: Hailey R. Lee, Evan R. Abt, Khalid Rashid, Amanda L. Creech, Keke Liang, Liu Wei, Arthur Cho, Willy Hugo, Timothy R. Donahue, Johannes Czernin, Caius G. Radu, Thuc M. Le. Detection of STING-induced immune activation via [18F]FDG-PET imaging [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2483.

20 September 2024 in Microchemical Journal
Verified
Journal Article
Closed access
YHYu He
Yu He
XRXiaoyong Rao
Xiaoyong Rao
YZYang Zhan
Yang Zhan
QTQing Tao
Qing Tao
YHYan He
Yan He
WLWei Liu
Wei Liu

9 January 2026 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
WZWentao Zhu
Wentao Zhu
JQJunhao Qiao
Junhao Qiao
XRXiaoyong Rao
Xiaoyong Rao
XHXiuwa Huang
Xiuwa Huang
PPPeiyu Peng
Peiyu Peng
WLWei Liu
Wei Liu
FMS-like tyrosine receptor kinase 3 (FLT3) mutations have been recognized as ideal drug discovery targets for the treatment of acute myeloid leukemia (AML). Starting from the reported inhibitor 13v, we rationally designed and synthesized ZZP-2, a pyridine-pyridazine hybrid that displayed single-digit nanomolar IC₅₀ values against FLT3-ITD-positive AML cell lines (MOLM-13 and MV4-11). ZZP-2 suppressed FLT3 autophosphorylation and downstream STAT5, ERK, and AKT signaling in a concentration-dependent manner, exerting antiproliferative effects through multiple mechanisms, including apoptosis induction and cell cycle arrest. However, ZZP-2's aqueous solubility is < 0.5 μg/mL, a very low value which may affect the rate and extent of drug absorption from suspension formulations throughout the gastrointestinal tract. To overcome this limitation, we developed an optimized nano-self-emulsifying drug-delivery system (SEDDS) that reproducibly formed fine droplets (23.77 ± 0.20 nm) upon dilution and achieved > 95 % drug loading efficiency. After oral administration, the SEDDS formulation increased the ZZP-2 plasma area under the curve (AUC0-∞) by 3.7-fold relative to a suspension formulation in Sprague-Dawley (SD) rats and significantly prolonged survival in MOLM-13-luciferase-bearing NSG mice compared to positive controls sunitinib and gilteritinib, without noticeable toxicity. Our study presents a novel FLT3-ITD inhibitor with high potency and in vivo stability.

19 December 2023 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
NZNan Zhou
Nan Zhou
RWRan Wang
Ran Wang
LLLin-Feng Liu
Lin-Feng Liu
WLWei Liu
Wei Liu
XLXiao-Jian Luo
Xiao-Jian Luo
MHMing-Zhen He
Ming-Zhen He

14 March 2026 in Next Research
Verified
Journal Article
Closed access
ZZZihao Zhang
Zihao Zhang
ZZZhijian Zhong
Zhijian Zhong
QMQingmin Meng
Qingmin Meng
XZXingnan Zhao
Xingnan Zhao
YZYao Zhang
Yao Zhang
WLWei Liu
Wei Liu